Antibacterial Treatment Using a Cannabinoid and an Active Agent

1 . A composition comprising a cannabinoid and a disruptor compound that removes or substantially removes or reduces the integrity of the outer membrane of a bacterium.

2 . (canceled)

3 . The composition of claim 1 wherein the composition is adapted for administration topically, orally, by injection, or by nasal or pulmonary administration.

4 . The composition of claim 1 wherein the cannabinoid is chosen from the list comprising: cannabidiol, cannabinol, cannabigerol, cannabichromene, and Δ9-tetrahydrocannabinol.

5 . The composition of claim 1 wherein the disruptor compound that removes or substantially removes or reduces the integrity of the outer membrane of the bacteria is selected from the group consisting of: β-lactams, fosfomycin, lysozyme, polymyxins, lipopeptides including cyclic lipopeptides, chelating agents, glycopeptides, tromethamine, diazaborine, protamine, ketodeoxyoctulosonate analogs, polylysine polymers, polyornithine polymers, nourseothricin, defensins, cecropins, magainins, melittin, bactenecins, seminalplasmin, apidaecin, abaecin, bactericidal/permeability-increasing protein (BPI), eosinophil major basic protein, eosinophil cationic protein (ECP), lactoferrin, azurocidin, cathepsin G, aminoglycosides, Tris, nitrilotriacetate, sodium hexametaphosphate (HMP), acetylsalicylate, ascorbate, fleroxacin, fluoroquinolones, monoglycerides, and immunological agents.

6 . A method for the treatment or prevention of an infection by a bacterium in a subject in need of such treatment comprising the step of:

a) administering an effective amount of a composition comprising a cannabinoid and a disruptor compound that removes or substantially removes or reduces the integrity of the outer membrane of a bacterium.

7 - 8 . (canceled)

9 . A kit comprising: (i) a cannabinoid and a disruptor compound that removes or substantially removes or reduces the integrity of the outer membrane of a bacteria for the treatment or prevention of a bacterial infection in a subject in need of such treatment or prevention; and (ii) instructions for use.

10 . The composition of claim 1 , wherein the Gram-negative bacteria is Escherichia coli and the disruptor compound is selected from:

a) Ticarcillin at a cannabidiol:disruptor ratio of more than 1:0.06 to less than 1:8000;

b) Colistin at a cannabidiol:disruptor ratio of more than 1:0.00097 to less than 1:4;

c) MCC_6442 at a cannabidiol:disruptor ratio of more than 1:0.016 to less than 1:4080; d) Cefotetan at a cannabidiol:disruptor ratio of more than 1:0.002 to less than 1:255;

e) Aztreonam at a cannabidiol:disruptor ratio of more than 1:0.00097 to less than 1:127;

f) Octapetin C4 at a cannabidiol:disruptor ratio of more than 1:0.03 to 1:64;

g) Spero SPR206 at a cannabidiol:disruptor ratio of more than 1:0.0004 to less than 1:4080;

h) Spero Potentiator SPR741 at a cannabidiol:disruptor ratio of more than 1:0.002 to 1:64;

i) FADDI-287 at a cannabidiol:disruptor ratio of 1:0.125 to less than 1:510; or

j) MCC_8980 at a cannabidiol:disruptor ratio of more than 1:0.03 to 1:2040.

11 . The composition of claim 1 , wherein the Gram-negative bacteria is Pseudomonas aeruginosa and the disruptor compound is selected from:

a) Ticarcillin at a cannabidiol:disruptor ratio of more than 1:0.25 to less than 1:32640;

b) Ceftazidime at a cannabidiol:disruptor ratio of more than 1:0.03 to less than 1:4080;

c) Aztreonam at a cannabidiol:disruptor ratio of more than 1:0.03 to less than 1:4080; or

d) MCC_8980 at a cannabidiol:disruptor ratio of more than 1:0.125 to 1:16.

12 . The composition of claim 1 , wherein the Gram-negative bacteria is Acinetobacter baumannii and the disruptor compound is selected from:

a) Cefuroxime at a cannabidiol:disruptor ratio of more than 1:0.25 to less than 1:2;

b) Colistin at a cannabidiol:disruptor ratio of 1:0.004 to 1:510;

c) MCC_6442 at a cannabidiol:disruptor ratio of more than 1:0.015 to 1:8;

d) Aztreonam at a cannabidiol:disruptor ratio of more than 1:0.06 to 1:16320;

e) Cefepime at a cannabidiol:disruptor ratio of more than 1:0.06 to less than 1:0.5;

f) Octapeptin C4 at a cannabidiol:disruptor ratio of more than 1:0.03 to 1:2;

g) Spero SPR206 at a cannabidiol:disruptor ratio of more than 1:0.002 to less than 1:2040; h) Spero Potentiator SPR741 at a cannabidiol:disruptor ratio of more than 1:0.015 to 1:64;

i) FADDI-287 at a cannabidiol:disruptor ratio of 1:0.125 to less than 1:510; and

j) MCC_8980 at a cannabidiol:disruptor ratio of more than 1:0.125 to 1:16.

13 . The composition of claim 1 , wherein the Gram-negative bacteria is Klebsiella pneumoniae and the disruptor compound selected from:

a) Colistin at a cannabidiol:disruptor ratio of more than 1:0.008 to less than 1:1020;

b) MCC_6442 at a cannabidiol:disruptor ratio of more than 1:0.03 to 1:16;

c) Spero SPR206 at a cannabidiol:disruptor ratio of more than 1:0.002 to less than 1:4080;

d) Spero Potentiator SPR741 at a cannabidiol:disruptor ratio of more than 1:0.016 to 1:32;

e) FADDI-287 at a cannabidiol:disruptor ratio of 1:0.125 to less than 1:510;

f) MCC_8980 at a cannabidiol:disruptor ratio of more than 1:0.25 to 1:2.